These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3188815)

  • 1. [The risk of drug overdosage in hepatic diseases].
    Bircher J
    Acta Gastroenterol Belg; 1988; 51(1):102-5. PubMed ID: 3188815
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of molsidomine in patients with liver dysfunction due to congestive heart failure.
    Huber T; Grosse-Heitmeyer W; Rietbrock S; Harder S
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):491-2. PubMed ID: 1490800
    [No Abstract]   [Full Text] [Related]  

  • 3. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient.
    Yogaratnam D; Miller MA; Smith BS
    Crit Care Nurs Clin North Am; 2005 Sep; 17(3):245-50. PubMed ID: 16115532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics.
    Atkinson AJ; Kushner W
    Annu Rev Pharmacol Toxicol; 1979; 19():105-27. PubMed ID: 378099
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of liver diseases on pharmacokinetics of drugs].
    Lazowski J; Rewerski W
    Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):95-9. PubMed ID: 2216955
    [No Abstract]   [Full Text] [Related]  

  • 6. [Ethmozine pharmacokinetics in liver insufficiency].
    Kurapov AP; Nekrasova OV; Gneushev ET; Ryzhenkova AP; Kukes VG
    Sov Med; 1990; (5):34-6. PubMed ID: 2202059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug metabolism in liver diseases].
    Paumgartner G
    Z Gastroenterol Verh; 1979; 16():42-7. PubMed ID: 95370
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
    Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
    J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of glymidine (glycodiazine) and tolbutamide in acute and chronic liver diseases.
    Held H; Eisert R; von Oldershausen HF
    Arzneimittelforschung; 1973 Dec; 23(12):1801-7. PubMed ID: 4801689
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug dosing in chronic hepatic disease (author's transl)].
    Gugler R; Eichelbaum M
    Leber Magen Darm; 1981 Apr; 11(2):81-7. PubMed ID: 7015045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of propoxyphene.
    Pearson RM
    Hum Toxicol; 1984 Aug; 3 Suppl():37S-40S. PubMed ID: 6480015
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effects of liver disease on pharmacokinetics of drugs and its therapeutic implications].
    Nunes AM
    Rev Port Cardiol; 1992 Feb; 11(2):177-84. PubMed ID: 1567639
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics of cicletanine hydrochloride.
    Fredj G
    Drugs Exp Clin Res; 1988; 14(2-3):181-8. PubMed ID: 3416722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of various physiological and pathological conditions on the bioavailability of drugs].
    Danysz A; Wierzba K
    Pol Tyg Lek; 1979 Jan; 34(4):141-3. PubMed ID: 432125
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug elimination in chronic liver diseases.
    Huet PM; Villeneuve JP; Fenyves D
    J Hepatol; 1997; 26 Suppl 2():63-72. PubMed ID: 9204411
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacokinetics of thiamphenicol. Behavior in a acute and chronic hepatic insufficiency].
    Menz HP; Bezler HJ; Hartmann I; von Oldershausen HF
    Arzneimittelforschung; 1974 Jan; 24(1):99-102. PubMed ID: 4406121
    [No Abstract]   [Full Text] [Related]  

  • 17. Terminal half-lives of drugs studied in patients with hepatic diseases.
    Closson RG
    Am J Hosp Pharm; 1977 May; 34(5):520-4. PubMed ID: 326043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolism of phenylbutazone in the liver (author's transl)].
    González Macías J; De Castro del Pozo S
    Med Klin; 1976 Sep; 71(36):1434-8. PubMed ID: 958107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical pharmacology of calcium inhibitors].
    Singlas E; Martre H; Taburet AM
    Arch Mal Coeur Vaiss; 1985 Nov; 78 Spec No():15-22. PubMed ID: 3937500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment.
    Durnin C; Hind ID; Ghani SP; Yates DB; Molz KH
    Proc West Pharmacol Soc; 2001; 44():83-4. PubMed ID: 11794005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.